Form 4: United Therapeutics EVP Sells Shares After Option Exercise

United Therapeutics' EVP & General Counsel, Paul A. Mahon, exercised stock options and sold 11,000 shares under a pre-arranged 10b5-1 plan.

Summary

• Paul A. Mahon, Executive Vice President and General Counsel of United Therapeutics Corp (UTHR), reported an insider transaction.
• On October 16, 2025, Mr. Mahon exercised 11,000 stock options at an exercise price of $135.42 per share.
• Immediately following the option exercise, Mr. Mahon sold all 11,000 shares of common stock acquired through the exercise.
• The sales were executed in multiple trades at weighted average prices ranging from $428.5087 to $435.42 per share.
• These transactions were conducted pursuant to a pre-arranged Rule 10b5-1 plan, which was entered into on December 24, 2024.
• After these transactions, Mr. Mahon directly beneficially owns 36,781 shares of common stock and 33,000 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The filing details a routine insider transaction (exercise of options and sale of shares) under a pre-arranged 10b5-1 plan. This is generally considered a neutral event, reflecting personal financial planning rather than a specific positive or negative signal about the company's operational performance or future prospects.

Positives

• The insider transaction was executed under a pre-arranged 10b5-1 plan, indicating a planned liquidity event rather than a reaction to new information.
• The sale prices significantly exceeded the exercise price of $135.42, indicating a substantial profit for the reporting person from the exercised options.

Negatives

• The transaction involves insider selling, which, while pre-planned, represents a reduction in the insider's direct equity holdings in the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing reports a routine insider transaction and does not provide information relevant to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The transaction is a routine insider sale under a 10b5-1 plan and is unlikely to have a significant direct impact on other shareholders.
• Reporting Person: Paul A. Mahon realized a significant profit from the exercise and sale of options, impacting his personal financial position.

Key Dates

Recommendation

The filing details a routine insider transaction involving the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 plan. This type of transaction is generally for personal financial planning and does not typically signal a change in the company's fundamental outlook or warrant a shift in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this event does not provide new information to alter an existing investment thesis.

Keywords

United Therapeutics, UTHR, Insider Transaction, Form 4, Stock Options, 10b5-1 Plan, Paul A. Mahon, EVP, General Counsel